Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2004-12-13
pubmed:abstractText
4-Bromo-2,5-dimethoxyphenethylamine (2C-B) is a psychoactive designer drug of abuse that is sold under the street names "Venus", "Bromo", "Erox", "XTC" or "Nexus". Concern has been raised because only little is known about its toxicity and metabolism in humans. In the present study we incubated 2C-B with human, monkey, dog, rabbit, rat and mouse hepatocytes to identify the metabolites formed and to determine possible toxic effects as evidenced by an ATP assay. Our data allow construction of the main metabolic pathways of 2C-B. Oxidative deamination results in the 2-(4-bromo-2,5-dimethoxyphenyl)-ethanol (BDMPE) and 4-bromo-2,5-dimethoxyphenylacetic acid (BDMPAA) metabolites. Additionally, 4-bromo-2,5-dimethoxybenzoic acid (BDMBA) can be produced also by oxidative deamination. Further metabolism of BDMPE and BDMPAA may occur by demethylation. Alternatively, the later metabolites can be generated by demethylation of 2C-B followed by oxidative deamination. Two remarkable interspecies differences in metabolism of 2C-B were observed (i) a hitherto unknown metabolite, 4-bromo-2,5-dimethoxy-phenol (BDMP), was identified after incubation only with mouse hepatocytes; (ii) 2-(4-bromo-2-hydroxy-5-methoxyphenyl)-ethanol (B-2-HMPE) was produced by hepatocytes from human, monkey and rabbit but not by dog, rat and mouse. Comparing the toxic effects of 2C-B between hepatocytes of the six examined species we observed only minor interspecies differences. However, large inter-individual differences in susceptibility of hepatocytes from three human donors were observed.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0300-483X
pubmed:author
pubmed:issnType
Print
pubmed:day
5
pubmed:volume
206
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
75-89
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:15590110-2,5-Dimethoxy-4-Methylamphetamine, pubmed-meshheading:15590110-Adenosine Triphosphate, pubmed-meshheading:15590110-Animals, pubmed-meshheading:15590110-Cells, Cultured, pubmed-meshheading:15590110-Deamination, pubmed-meshheading:15590110-Dogs, pubmed-meshheading:15590110-Dose-Response Relationship, Drug, pubmed-meshheading:15590110-Gas Chromatography-Mass Spectrometry, pubmed-meshheading:15590110-Hepatocytes, pubmed-meshheading:15590110-Humans, pubmed-meshheading:15590110-Macaca fascicularis, pubmed-meshheading:15590110-Male, pubmed-meshheading:15590110-Mice, pubmed-meshheading:15590110-Mice, Inbred Strains, pubmed-meshheading:15590110-Middle Aged, pubmed-meshheading:15590110-Molecular Structure, pubmed-meshheading:15590110-Oxidation-Reduction, pubmed-meshheading:15590110-Rabbits, pubmed-meshheading:15590110-Rats, pubmed-meshheading:15590110-Rats, Sprague-Dawley, pubmed-meshheading:15590110-Species Specificity, pubmed-meshheading:15590110-Street Drugs
pubmed:year
2005
pubmed:articleTitle
Metabolic pathways of 4-bromo-2,5-dimethoxyphenethylamine (2C-B): analysis of phase I metabolism with hepatocytes of six species including human.
pubmed:affiliation
REQUIMTE, Toxicology Department, Faculty of Pharmacy, University of Porto, Rua Aníbal Cunha 164, 4050-047 Porto, Portugal. helenacarmo@ff.up.pt
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't